Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74]: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
01. NICE’s response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD – Bristol Myers-Squibb
03. Consultee comments on the ACD – OcuMel UK
04. Consultee comments on the ACD – British Association of Dermatologists
05. Consultee comments on the ACD - Royal College of Physiciabns NCRI-RCP-RCR-ACP-JCCO-Melanoma Focus
06. Consultee comments on the ACD- Department of Health
07. Public comments on the ACD received via the NICE website
08. Open letter – Melanoma UK
09. MP letter - Pauline Latham
10. ERG review of manufacturer’s response by NHS Centre for Reviews & Dissemination and Centre for Health Economics, University of York
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74]: evaluation report
13 June 2014 (3.82 Mb 19 mins ) |
This page was last updated: 12 June 2014